This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Edotecarin and Cisplatin in Treating Patients With Advanced or Metastatic Solid Tumors

This study has been completed.
National Cancer Institute (NCI)
Information provided by:
National Cancer Institute (NCI) Identifier:
First received: November 4, 2003
Last updated: December 18, 2013
Last verified: December 2009

RATIONALE: Drugs used in chemotherapy, such as edotecarin and cisplatin, use different ways to stop tumor cells from dividing so they stop growing or die. Combining edotecarin with cisplatin may kill more tumor cells.

PURPOSE: Phase I trial to study the effectiveness of combining edotecarin with cisplatin in treating patients who have advanced or metastatic solid tumors.

Condition Intervention Phase
Esophageal Cancer Gastric Cancer Unspecified Adult Solid Tumor, Protocol Specific Drug: cisplatin Drug: edotecarin Phase 1

Study Type: Interventional
Study Design: Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase I Dose Escalation Study of Edotecarin (PHA-782615) and Cisplatin in Adult Patients With Advanced/Metastatic Solid Tumors

Resource links provided by NLM:

Further study details as provided by National Cancer Institute (NCI):

Study Start Date: August 2003
Study Completion Date: December 2009
Primary Completion Date: December 2005 (Final data collection date for primary outcome measure)
Detailed Description:



  • Determine the maximum tolerated dose and recommended phase II dose of edotecarin when administered with cisplatin (administered in 2 different schedules) in patients with advanced or metastatic solid tumors.


  • Determine the safety profile of this regimen in these patients.
  • Determine the plasma pharmacokinetics of this regimen in these patients.
  • Determine the antitumor activity of this regimen in these patients.

OUTLINE: This is an open-label, multicenter, dose-escalation study of edotecarin. Patients are assigned to 1 of 2 schedules.

  • Schedule A: Patients receive cisplatin IV over 30 minutes and edotecarin IV over 1 hour on days 1 and 8.
  • Schedule B: Patients receive cisplatin IV over 2 hours and edotecarin IV over 1 hour on day 1.

In both schedules, courses repeat every 3 weeks in the absence of disease progression or unacceptable toxicity.

Cohorts of 3-6 patients in each schedule receive escalating doses of edotecarin until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2 of 6 patients experience dose-limiting toxicity. Once the MTD is determined, 10 additional patients with metastatic esophageal or gastric cancer receive treatment as above at the MTD.

Patients are followed every 2 months for 1 year or until disease progression.

PROJECTED ACCRUAL: A maximum of 80 patients (40 per schedule) will be accrued for this study.


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No


  • Diagnosis of one of the following:

    • Histologically or cytologically confirmed active solid tumor malignancy
    • Histologically confirmed esophageal or gastric cancer* meeting all the following criteria:

      • Previously untreated disease
      • Metastatic disease
      • Measurable disease

        • At least 1 unidimensionally measurable lesion at least 20 mm by conventional techniques OR 10 mm by spiral CT scan NOTE: *Patients with esophageal or gastric cancer are enrolled after the maximum tolerated dose has been determined
  • No known brain or leptomeningeal disease



  • 18 and over

Performance status

  • ECOG 0-1

Life expectancy

  • Not specified


  • Absolute neutrophil count at least 1,500/mm^3
  • Platelet count at least 100,000/mm^3
  • Hemoglobin at least 9.0 g/dL


  • Bilirubin no greater than 1.5 times upper limit of normal (ULN) (regardless of liver involvement by tumor)
  • SGOT no greater than 3 times ULN (5 times ULN if there is liver involvement by tumor)
  • Albumin at least 3.0 g/dL


  • Creatinine no greater than 1.5 mg/dL


  • None of the following within the past 12 months:

    • Myocardial infarction
    • Severe/unstable angina
    • Symptomatic congestive heart failure
    • Cerebrovascular accident
    • Transient ischemic attack
    • Deep vein thrombosis
    • Other significant thromboembolic event
  • No ongoing grade 2 or greater cardiac dysrhythmia
  • No atrial fibrillation


  • No pulmonary embolism within the past 12 months


  • No active inflammatory bowel disease
  • No partial or complete bowel obstruction
  • No chronic diarrhea


  • Not pregnant or nursing
  • Negative pregnancy test
  • Fertile patients must use effective contraception
  • HIV negative
  • No grade 2 or greater acute toxic effects
  • No active infection
  • No other concurrent acute or chronic medical or psychiatric condition or laboratory abnormality that would preclude study participation


Biologic therapy

  • No prior treatment with any of the following systemic therapies for metastatic cancer*:

    • Antibody therapy
    • Immunotherapy
    • Gene therapy
    • Vaccine therapy
    • Cytokine therapy
    • Inhibitors of vascular endothelial growth factor/Flk-1 pathway
  • No concurrent sargramostim (GM-CSF)
  • No concurrent antibody therapy or immunotherapy NOTE: *Patients with esophageal or gastric cancer only


  • No more than 1 prior chemotherapy regimen for metastatic disease*
  • No prior high-dose chemotherapy requiring hematopoietic stem cell rescue
  • No other concurrent chemotherapy NOTE: *No prior chemotherapy for metastatic disease for patients with esophageal or gastric cancer

Endocrine therapy

  • No concurrent hormonal treatment


  • No prior radiotherapy to more than 25% of bone marrow reserve
  • No prior radiotherapy to the sole measurable lesion*
  • No concurrent radiotherapy NOTE: *Patients with esophageal or gastric cancer only


  • More than 12 months since prior coronary/peripheral artery bypass graft surgery


  • Recovered from prior therapy
  • More than 6 months since last dose of prior adjuvant therapy*
  • No prior treatment with any of the following systemic therapies for metastatic cancer*:

    • Cyclooxygenase-2 inhibitors
    • Matrix metalloprotease inhibitors
    • Epidermal growth factor receptor inhibitors
    • Other experimental agents
  • No other concurrent anticancer therapy
  • No concurrent enrollment in another clinical trial
  • No other concurrent experimental drugs NOTE: *Patients with esophageal or gastric cancer only
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00072332

United States, New York
Memorial Sloan-Kettering Cancer Center
New York, New York, United States, 10021
Sponsors and Collaborators
Memorial Sloan Kettering Cancer Center
National Cancer Institute (NCI)
Principal Investigator: David H. Ilson, MD, PhD Memorial Sloan Kettering Cancer Center
  More Information Identifier: NCT00072332     History of Changes
Other Study ID Numbers: CDR0000339607
Study First Received: November 4, 2003
Last Updated: December 18, 2013

Keywords provided by National Cancer Institute (NCI):
unspecified adult solid tumor, protocol specific
stage IV esophageal cancer
stage IV gastric cancer

Additional relevant MeSH terms:
Stomach Neoplasms
Esophageal Neoplasms
Gastrointestinal Neoplasms
Digestive System Neoplasms
Neoplasms by Site
Digestive System Diseases
Gastrointestinal Diseases
Stomach Diseases
Head and Neck Neoplasms
Esophageal Diseases
Antineoplastic Agents processed this record on August 18, 2017